Sight Sciences, Inc., a Menlo Park, CA-based commercial stage ophthalmic medical device company, closed a $7m Series B financing round.
The round was led by Hicks Equity Partners, with participation from Series A investors Scientific Health Development, Allegro Investment Fund, and various other institutional and angel investors.
The company intends to use the funds to build out the management team, scale manufacturing, support product development, and initiate a series of clinical studies.
Led by Paul Badawi, President and CEO, Sight Sciences is a medical device company dedicated to the development of technology-driven solutions that address the underlying physiology of ophthalmic disease.
The company operates surgical and non-surgical device business lines. Its surgical product portfolio consists of the TRAB™360 and VISCO™360 surgical devices. Its non-surgical product portfolio consists of technologies in the advanced stages of development for evaporative dry eye.